Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24081406 | 0.80 | HRH3 (0.47) | KDM1AHRH3CYP2D6HRH1ALOX5 | |
| SCHEMBL14263757 | 0.78 | MAOA (0.52) | KDM1AHRH3CYP2D6HRH1MAOA | |
| SCHEMBL4045668 | 0.78 | MAOA (0.52) | KDM1AHRH3CYP2D6HRH1MAOA | |
| SCHEMBL12471689 | 0.77 | HRH3 (0.52) | KDM1AHRH3CYP2D6HRH1ALOX5 | |
| SCHEMBL6705268 | 0.76 | PSEN1 (0.49) | HRH3CYP2D6HRH1MAOAMAOB | |
| SCHEMBL12471199 | 0.76 | HRH3 (0.51) | KDM1AHRH3CYP2D6HRH1ALOX5 | |
| SCHEMBL6107804 | 0.76 | KDM1A (0.48) | KDM1AHRH3CYP2D6HRH1MAOA | |
| SCHEMBL5069775 | 0.75 | MAOB (0.45) | MAOAMAOB | |
| SCHEMBL18983590 | 0.75 | HRH3 (0.59) | HRH3CYP2D6HRH1FAAH | |
| SCHEMBL31344785 | 0.75 | HRH3 (0.59) | KDM1AHRH3CYP2D6HRH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | KDM1A 2768/4885HRH3 1335/4885CYP2D6 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.